Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

医学 贝伐单抗 外科 养生 揭穿 化疗 卵巢癌 围手术期 卡铂 内科学 癌症 顺铂
作者
Gennaro Daniele,Domenica Lorusso,Giovanni Scambia,Sabrina Chiara Cecere,Maria Ornella Nicoletto,Enrico Breda,Nicoletta Colombo,Grazia Artioli,L. Cannella,Giovanni Lo Re,Francesco Raspagliesi,Giuseppa Maltese,Vanda Salutari,Stefano Greggi,Alessandra Baldoni,Alice Bergamini,Maria Carmela Piccirillo,Germana Tognon,Irene Floriani,Simona Signoriello,Francesco Perrone,Sandro Pignata
出处
期刊:Gynecologic Oncology [Elsevier]
卷期号:144 (2): 256-259 被引量:36
标识
DOI:10.1016/j.ygyno.2016.12.011
摘要

Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery.400 chemonaïve epithelial ovarian cancer patients, age≥18, ECOG PS 0-2 were eligible to receive C (AUC 5 d1, q21) plus P (175mg/m2 d1, q21) and B (15mg/kg d1 q21) for 6cycles followed by B maintenance until cycle 22nd.79 patients (20%) underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70% of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease ≤1cm was achieved in 64 patients (86.5%). Four percent of the patients experienced fever and 4% required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each.In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
杳鸢应助清脆的棒球采纳,获得20
2秒前
邹友亮完成签到,获得积分10
2秒前
HL发布了新的文献求助10
3秒前
结实星星发布了新的文献求助10
3秒前
5秒前
6秒前
7秒前
龙仔发布了新的文献求助30
7秒前
RAB发布了新的文献求助10
8秒前
DUTlh发布了新的文献求助10
8秒前
酷酷薯片发布了新的文献求助10
8秒前
9秒前
wenlin完成签到,获得积分10
10秒前
木雨洛完成签到,获得积分10
10秒前
Billy应助义气水杯采纳,获得30
11秒前
12秒前
HL完成签到,获得积分10
14秒前
郭阳发布了新的文献求助10
14秒前
16秒前
16秒前
16秒前
18秒前
21秒前
zhanglh应助saybia采纳,获得10
21秒前
21秒前
CX330发布了新的文献求助10
22秒前
RJH发布了新的文献求助10
22秒前
22秒前
Owen应助一一采纳,获得10
22秒前
22秒前
今天你读文献了吗完成签到,获得积分10
23秒前
威武富完成签到,获得积分10
24秒前
结实星星发布了新的文献求助10
24秒前
风中的苞络完成签到,获得积分20
25秒前
宋兽兽发布了新的文献求助10
25秒前
25秒前
Boooooo发布了新的文献求助10
26秒前
baitaowl完成签到 ,获得积分10
27秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 850
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3252365
求助须知:如何正确求助?哪些是违规求助? 2895103
关于积分的说明 8285269
捐赠科研通 2563865
什么是DOI,文献DOI怎么找? 1391939
科研通“疑难数据库(出版商)”最低求助积分说明 651991
邀请新用户注册赠送积分活动 629208